JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

Home・Aktien・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Open

4.39 0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.32

Max

4.44

Schlüsselkennzahlen
By Trading Economics
Einkommen	27M 2.5M
Verkäufe	9M 11M
Gewinnspanne	23.494
Angestellte	44
EBITDA	27M 2.6M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	233M 872M
Vorheriger Eröffnungskurs	4.16
Vorheriger Schlusskurs	4.39

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

3.255 / 3.365 Unterstützung & Widerstand

Arbutus Biopharma Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Okt. 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. Okt. 2025, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. Okt. 2025, 21:20 UTC

Ergebnisse

Correction to IBM 3Q Sales Jump Article

22. Okt. 2025, 20:57 UTC

Ergebnisse

SAP Posts Higher 3Q Revenue, Operating Profit

22. Okt. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Okt. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. Okt. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:15 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. Okt. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. Okt. 2025, 22:02 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. Okt. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. Okt. 2025, 21:58 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. Okt. 2025, 21:57 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. Okt. 2025, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. Okt. 2025, 21:47 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. Okt. 2025, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. Okt. 2025, 21:28 UTC

Market Talk

Ergebnisse

Correction to Alcoa Tariff Market Talk

22. Okt. 2025, 21:25 UTC

Ergebnisse

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. Okt. 2025, 21:17 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. Okt. 2025, 21:09 UTC

Market Talk

Ergebnisse

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. Okt. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. Okt. 2025, 20:59 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 20:51 UTC

Ergebnisse

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Okt. 2025, 20:44 UTC

Ergebnisse

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer-Vergleich

Kursveränderung

Arbutus Biopharma Corp Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Arbutus Biopharma Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

3.255 / 3.365Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.